Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

Ella Troy, Joseph Caporale, Yasemin Sezgin, Marcelo S. F. Pereira, Gregory Behbehani, Justin Lyberger, Dean A. Lee, Meisam Naeimi Kararoudi

Blood Neoplasia (2024) 1 (4): 100032.

https://doi.org/10.1016/j.bneo.2024.100032

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy

Elizabeth A. Brem, Kevin Shieh, Dennis Juarez, Roberta Buono, Deepa Jeyakumar, Susan O’Brien, Thomas H. Taylor, David A. Fruman

Blood Neoplasia (2024) 1 (4): 100036.

https://doi.org/10.1016/j.bneo.2024.100036

Published: 2024

Includes: Supplemental data

Journal Articles

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

Paola Ghione, Kurt S. Bantilan, Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron, Paul Hamlin, Anita Kumar, Matthew Matasar, Colette Owens, Alison Moskowitz, Lorenzo Falchi, David Straus, Steven Horwitz, Gilles Salles, Ahmet Dogan, Andrew D. Zelenetz

Blood Neoplasia (2024) 1 (4): 100031.

https://doi.org/10.1016/j.bneo.2024.100031

Published: 2024

Journal Articles

BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis

Wangisa Dunuwille, William C. Wilson, Hassan Bjeije, Nancy Issa, Wentao Han, Tyler M. Parsons, Andrew L. Young, Infencia Xavier Raj, Aishwarya Krishnan, Tarang Gaur, Eunice S. Wang, Andrew P. Weng, Matthew C. Stubbs, Hamza Celik, Amanda F. Cashen, John R. Edwards, Grant A. Challen

Blood Neoplasia (2024) 1 (4): 100040.

https://doi.org/10.1016/j.bneo.2024.100040

Published: 2024

Includes: Supplemental data

Journal Articles

COVID-19 vaccination in patients with classic and variant hairy cell leukemia

Robert J. Kreitman, Lacey James, Julie Feurtado, Holly Eager, Olena Sierra Ortiz, Mory Gould, Isaac Shpilman, Hong Zhou, Peter D. Burbelo, Jeffrey I. Cohen, Hao-Wei Wang, Constance M. Yuan, Evgeny Arons

Blood Neoplasia (2024) 1 (4): 100035.

https://doi.org/10.1016/j.bneo.2024.100035

Published: 2024

Journal Articles

Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma

Amrita Y. Krishnan, Krina K. Patel, Meera Mohan, Sundar Jagannath, Ruben Niesvizky, Rebecca W. Silbermann, Ziji Yu, Tao Long, Scott R. P. McDonnell, Deborah Berg, Keith E. Stockerl-Goldstein

Blood Neoplasia (2024) 1 (4): 100043.

https://doi.org/10.1016/j.bneo.2024.100043

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy

Blood Neoplasia (2024) 1 (4): 100044.

https://doi.org/10.1016/j.bneo.2024.100044

Published: 2024

Includes: Supplemental data

Journal Articles

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

Kuo-Kai Chin, Yannis Valtis, Andriy Derkach, Meira Yisraeli Salman, Leora Boussi, Jenna Ciervo, Mark B. Geyer, Jae H. Park, Martin S. Tallman, Jacob L. Glass, Aaron D. Goldberg, Eytan M. Stein

Blood Neoplasia (2024) 1 (4): 100038.

https://doi.org/10.1016/j.bneo.2024.100038

Published: 2024

Includes: Supplemental data

Journal Articles

Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML

Sara H. Small, Ricardo E. Perez, Elspeth M. Beauchamp, Aneta H. Baran, Stephen D. Willis, Mariafausta Fischietti, Michael Schieber, Masha Kocherginsky, Diana Saleiro, Leonidas C. Platanias

Blood Neoplasia (2024) 1 (4): 100037.

https://doi.org/10.1016/j.bneo.2024.100037

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation

Jinjun Cheng, Rachel Mariani, Jyotinder Nain Punia, Marimar de la Cruz Bonilla, Pichayut Nithagon, Metin Ozdemirli, Wen Shuai, Larry Wang, Oussama Abla, Shunyou Gong

Blood Neoplasia (2024) 1 (4): 100039.

https://doi.org/10.1016/j.bneo.2024.100039

Published: 2024

Includes: Supplemental data

Journal Articles

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

Eunice Lai, Yu Yang Soon, Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Cinnie Yentia Soekojo, Melissa Ooi, Wee Joo Chng, Sanjay de Mel

Blood Neoplasia (2024) 1 (4): 100042.

https://doi.org/10.1016/j.bneo.2024.100042

Published: 2024

Includes: Supplemental data

Journal Articles

Cerebrospinal Fluid Attenuates the Efficacy of Methotrexate against Acute Lymphoblastic Leukemia Cells

Jongseok Kang, Jason Ostergaard, Xiaohong Wang, Peter M. Gordon

Blood Neoplasia 100057.

https://doi.org/10.1016/j.bneo.2024.100057

Published: 2024

Includes: Supplemental data

Journal Articles

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi, Ryota Chijimatsu, Yusuke Naoi, Yoshihiro Otani, Ryo Mizuta, Kentaro Fujii, Joji Ishida, Hiroyuki Murakami, Hideki Ujiie, Kazuhiro Ikeuchi, Tomohiro Urata, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Nobuharu Fujii, Ken-ichi Matsuoka, Yasuharu Sato, Maeda Yoshinobu, Daisuke Ennishi

Blood Neoplasia 100058.

https://doi.org/10.1016/j.bneo.2024.100058

Published: 2024

Includes: Supplemental data

Journal Articles

JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study

Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai

Blood Neoplasia 100053.

https://doi.org/10.1016/j.bneo.2024.100053

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Max J. Gordon, Sigrid Dubois, Milos D. Miljkovic, Samuel Ng, Bonita Bryant, Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Kevin Conlon, Thomas Waldmann, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski

Blood Neoplasia 100054.

https://doi.org/10.1016/j.bneo.2024.100054

Published: 2024

Journal Articles

Addition of navitoclax to ruxolitinib in patients with myelofibrosis with progression or suboptimal response

Naveen Pemmaraju, Tim C.P. Somervaille, Francesca Palandri, Claire Harrison, Rami S. Komrokji, Andrew Perkins, Rosa M. Ayala Diaz, David Lavie, Akihiro Tomita, Yang Feng, Qin Qin, Jason Harb, Akshanth R. Polepally, Jalaja Potluri, Jacqueline S. Garcia

Blood Neoplasia 100056.

https://doi.org/10.1016/j.bneo.2024.100056

Published: 2024

Includes: Supplemental data

Journal Articles

Pralatrexate Injection Combined with Oral Leucovorin for Mucositis Management in the Treatment of Peripheral and Cutaneous T-Cell Lymphomas–Results from a Multicenter Phase 2 Trial

Swaminathan P. Iyer, Shaker Dakhil, Michi M. Shinohara, Jasmine Zain, Mark Acosta, Francine Foss

Blood Neoplasia 100055.

https://doi.org/10.1016/j.bneo.2024.100055

Published: 2024

Journal Articles

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma

Blood Neoplasia 100051.

https://doi.org/10.1016/j.bneo.2024.100051

Published: 2024

Includes: Supplemental data

Journal Articles

Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells

Anne P. de Groot, Chelsea R. Wilson, Ellen Weersing, Jacobine S. Pouw, Albertina Dethmers-Ausema, Huong Nguyen, Evan F. W. Chen, Alok Shaurya, Linda Smit, Fraser Hof, Gerald de Haan

Blood Neoplasia 100052.

https://doi.org/10.1016/j.bneo.2024.100052

Published: 2024

Includes: Supplemental data

Journal Articles

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma

Son Tran, Patrick Sipila, Melanie M. Frigault, Beatrix Stelte-Ludwig, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Ranjan Maity, Nizar J. Bahlis, Paola Neri, Aru Narendran

Blood Neoplasia 100050.

https://doi.org/10.1016/j.bneo.2024.100050

Published: 2024

Includes: Supplemental data

NARROW

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis

COVID-19 vaccination in patients with classic and variant hairy cell leukemia

Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML

Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

Cerebrospinal Fluid Attenuates the Efficacy of Methotrexate against Acute Lymphoblastic Leukemia Cells

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

JAK1/2 Inhibitor Ruxolitinib for the Treatment of Systemic Chronic Active Epstein-Barr Virus Disease: A Phase II Study

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Addition of navitoclax to ruxolitinib in patients with myelofibrosis with progression or suboptimal response

Pralatrexate Injection Combined with Oral Leucovorin for Mucositis Management in the Treatment of Peripheral and Cutaneous T-Cell Lymphomas–Results from a Multicenter Phase 2 Trial

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma

Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only